Easy YoY comps along with new product introductions help drive sequential growth 

SmartTRAK reports that In Q319, the WW Trauma Market (defined as fixation of the pelvis, femur & proximal/shaft portion of the tibia) increased +3.7% (as reported), with the US posting +4.6% growth. Q319 WW share leaders remained relatively steady compared to last year, with top trauma player DePuy Synthes, followed by Stryker, Zimmer Biomet and Smith & Nephew. The WW Trauma Market Segment shares were...

Among the many topics covered in the complete, comprehensive  Q319 Trauma Market Recap*  are:

Another quarter of strong growth, but slower growth clouds building up on the horizon here and there. Both Smith+Nephew and ConvaTec have newly appointed CEOs.

For Q319, according to SmartTRAK’s Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +5.9% YoY.

Acelity remained the WW AWC market leader, up +6.3% YoY, driven by  Prevena and the Crawford acquisition. WW Advanced Dressings saw several strong shifts in the ranking of companies, with ConvaTec moving up to the 2nd position, surpassing Smith + Nephew (S+N), after ConvaTec recovering, but S+N facing continued declining growth. Mölnlycke led the market and Coloplast was the strongest growing of the top four. The total market was up +3.2% YoY. US Skin/Dermal Substitute (CTP) revenue increased, with xenografts, especially  Organogenesis’  PuraPly, driving gains. WW NPWT was up  +8.2% YoY, with traditional devices up +3.4% and single-use...

Among the many topics covered in the complete, comprehensive Q319 Advanced Wound Care Market Recap* are:

SmartTRAK is excited to announce the launch of their new public website,  SmartTRAK.com. The new SmartTRAK.com features improved functionality,  enhanced custom content and a clean uncluttered design. It also features a more intuitive navigation for current customers and new visitors alike.

With a boost from an extra selling day during the third quarter, the US OrthoBio Market continues to be healthy, with Q319 revenue up +5.8% YOY. Year-to-date revenue is up +5.5% compared to the same time period for 2018. In addition to the specific factors that were discussed in the Q219 OrthoBio Recap, the segment’s success may be attributed to robustness in the broader economy and more people feeling comfortable scheduling procedures. As reported in Needham’s Q319 Review, in Q319 vs. Q219, overall orthopedic market growth improved to 5.0% vs. 3.1%, with spine improving to ...

Among the many topics covered in the complete, comprehensive Q319 OrthoBio Market Recap* are:

The US Total Joints Market grew +3.4% in Q319, according to SmartTRAK Financial Dashboard, a sequential improvement over Q2’s 1.8% growth. While the extra selling day in the quarter boosted revenue for most Companies, slightly improved pricing and new product introductions also contributed. Wells Fargo’s Larry Biegelsen estimated recon pricing – based on Stryker, Zimmer Biomet, JNJ/DePuy Synthes, and Smith & Nephew– improved to -1.8% YoY. This sequential improvement in growth and pricing is encouraging especially in the face of a difficult comp from Q318 ...

Among the many topics covered in the complete, comprehensive Q319 Total Joints Market Recap* are:

The US Surgical Matrices Market grew tepidly in Q319,  up +1.2% YoY,  down from its +3.5% growth in Q219. 

The overall US Surgical Matrices market had minimal growth for the quarter at +1.2% YoY, a decline from Q219. The Breast segment contracted -1.5% YoY and a 34.7% share of the entire Surgical Matrices market. The Hernia Repair market continued its modest growth at +2.6% YoY and a 65.3% share of the US Surgical Matrices Market in Q319.

In Q319, Allergan’s hold on the Breast Matrices segment slipped further due to supply chain issues with its AlloDerm ADM, but the Company maintained its leadership of the Surgical Matrices market a 32.3% share. BD continued its growth in their biosynthetic hernia matrices business and maintained No. 2 market position, with revenues of ...

The WW Spine Hardware market saw a return to growth in Q319 with +3.6% growth, the highest growth rate this market has seen in at least 2 years. An uptick in procedure volumes across the board drove robust US market growth of +5.7%. WFS analysts estimate the Q319 Spine market (excluding Infuse) accelerated 90bps sequentially on a stacked two-year basis with Medtronic, Globus and NuVasive taking share from DePuy Synthes, Stryker and Zimmer Biomet.

Whether you are a patient, a provider or product manufacturer it’s difficult to make it through the day without being reminded that healthcare is expensive. Many patients see it in their rising premiums, copays and deductibles. Providers feel it when their reimbursement gets cut or is capped, and product manufacturers experience it when they hear, “it’s too expensive.”

I’ll be the first to admit that I am not a New England Patriots fan. As a matter of fact I get rather irritated when they win year after year. Nevertheless, it’s hard to not appreciate the spirit of teamwork that has propelled the Patriots organization to win six Super Bowl titles. As we know, teamwork does not suggest the absence of conflict; however, it does express the willingness of a group of people, with individual talents, to work together to achieve a goal. Teamwork between clinicians, policy representatives and product manufacturers is crucial to winning the battle of healing wounds, salvaging limbs and saving lives. Three key takeaways from Day 2 of Desert Foot 2019 lend support to this point.

Clinical thought-leaders and product developers convened in the heart of downtown Phoenix, Arizona at Desert Foot 2019 to share knowledge and showcase innovative technologies that aim to improve the quality of life of patients with lower extremity disorders. As a demonstration of the eagerness and commitment to share knowledge, Day 1 began bright and early at 6:00 am with a session highlighting cases in limb preservation and ended at 6:45 pm with a session questioning if there was a resurgence in amputations in patients with diabetic foot. Whether planned or not, this was a thoughtful way to bookend the day by emphasizing the potential good and bad outcomes of this vulnerable patient population...